Cg Oncology shares rise 5.20% premarket after announcing positive 24-month complete response rate for cretostimogene.

Cg Oncology, Inc. rose 5.20% in premarket trading, with the company announcing updated data on BOND-003 Cohort C showing 12 additional patients with high-risk non-muscle invasive bladder cancer (HR NMIBC) were in complete response. The company also reported a robust 24-month complete response (CR) rate of 41.8% for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment.